About dordaviprone
H3K27M-mutant glioma anticancer medicine
Used for
- Treats adults with diffuse midline glioma that has an H3K27M mutation and progressed after treatment.
Usual adult dose
Usual dose: 625 mg by mouth once weekly, on an empty stomach.
Usual dose in children
For patients aged 1 year and older, dose is based on body surface area; specialist dosing is required.
Common side effects
- Fatigue
- Headache
- Nausea
- Vomiting
Important warnings
- Can cause QT prolongation and potentially serious abnormal heart rhythms.
- May cause neurological symptoms, including worsening weakness or seizures.
- Use only under specialist supervision; monitoring may include heart rhythm and blood tests.
- The approved indication and age limits may vary by country.
Pregnancy
May harm an unborn baby; pregnancy should be avoided during treatment and for one month afterward.
Breastfeeding
Do not breastfeed during treatment and for one month after the final dose.
Interactions
- Medicines that prolong the QT interval may increase heart-rhythm risks.
- Strong CYP3A4 inhibitors or inducers may alter dordaviprone levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.